<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>將其添加為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>美國週三的盤後交易中，多個小型和微型生物科技公司出現了一波上漲，既有催化劑驅動的波動，也有情緒驅動的反彈。雖然一些公司因即將到來的臨牀里程碑或最近的數據發佈而上漲，但其他公司儘管沒有新的公司動態，仍然上漲，反映出在延長交易期間對高波動性生物科技公司的重新關注。</p>
<p><em>以下是顯著的盤後漲幅股：</em></p>
<p><strong>Agape ATP Corp. (ATPC) — 盤後上漲 29.41%</strong></p>
<p>盤後交易：$0.088 (+29.41%)</p>
<p>收盤：$0.0680 (-94.83%)</p>
<p>儘管週三沒有公司特定的新聞，Agape ATP 在盤後交易中大幅上漲。這一走勢似乎是美聯儲降息後微型股的廣泛風險偏好反應，改善了市場投機性板塊的情緒。</p>
<p><strong>Corbus Pharmaceuticals Holdings, Inc. (CRBP) — 盤後上漲 12.76%</strong></p>
<p>盤後交易：$11.57 (+12.76%)</p>
<p>收盤：$10.26 (+1.58%)</p>
<p>Corbus 在關鍵臨牀更新前獲得了動力。該公司宣佈計劃在 2025 年 12 月 11 日市場開盤前發佈 CRB-913 的 1a 期 SAD/MAD 研究結果，並將在東部時間上午 8:00 召開電話會議。對數據的期待可能促成了強勁的盤後走勢。</p>
<p><strong>Anebulo Pharmaceuticals, Inc. (ANEB) — 盤後上漲 8.37%</strong></p>
<p>盤後交易：$2.33 (+8.37%)</p>
<p>收盤：$2.15 (-6.52%)</p>
<p>儘管週三沒有新聞，Anebulo 在盤後交易中大幅反彈。這一漲幅與美聯儲利率決定後小型生物科技情緒的整體上升相一致。</p>
<p><strong>Cue Biopharma, Inc. (CUE) — 盤後上漲 13.12%</strong></p>
<p>盤後交易：$0.54 (+13.12%)</p>
<p>收盤：$0.4773 (-3.50%)</p>
<p>Cue Biopharma 在沒有新的公司動態的情況下，盤後交易中出現了兩位數的跳漲。這一走勢似乎是宏觀驅動的，因為投資者重新回流到被打壓的生物科技股。</p>
<p><strong>Curis, Inc. (CRIS) — 盤後上漲 7.68%</strong></p>
<p>盤後交易：$1.3999 (+7.68%)</p>
<p>收盤：$1.30 (-2.26%)</p>
<p>Curis 在盤後交易中上漲，延續了其在 12 月 9 日第 67 屆 ASH 年會上發佈的更新臨牀數據的勢頭。海報強調了該公司前線 AML 三聯療法研究（CA-4948-104）的進展，繼續吸引投資者關注。</p>
<p><strong>Skye Bioscience, Inc. (SKYE) — 盤後上漲 7.02%</strong></p>
<p>盤後交易：$1.22 (+7.02%)</p>
<p>收盤：$1.14 (-5.79%)</p>
<p>儘管週三沒有新聞，Skye Bioscience 在盤後交易中出現了適度的反彈，可能受益於與美聯儲驅動的市場反彈相關的生物科技整體上漲。</p>
<p><strong>Cerus Corporation (CERS) — 盤後上漲 3.17%</strong></p>
<p>盤後交易：$1.95 (+3.17%)</p>
<p>收盤：$1.89 (+1.61%)</p>
<p>Cerus 在宣佈與美國血液中心（BCA）達成團體採購協議後，繼續其上升趨勢。該協議涵蓋了公司的全系列 INTERCEPT 產品，旨在擴大 BCA 全國網絡中病原體去除技術的可及性。</p>
<p>如需評論和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

ANEB

<p>週三的盤後交易中，小型股和微型股生物科技股票上漲，主要受到臨牀里程碑的預期和情緒反彈的推動。值得注意的漲幅股票包括 Agape ATP、Corbus Pharmaceuticals、Anebulo Pharmaceuticals、Cue Biopharma、Curis、Skye Bioscience 和 Cerus Corporation。這些漲幅受到美聯儲降息和特定公司動態的影響，例如 Corbus 即將發佈的臨牀更新和 Cerus 的新採購協議</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>將其添加為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>U.S. <em>after-hours trading</em> on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinical milestones or recent data presentations, others climbed despite having no new corporate developments, reflecting renewed interest in high-volatility biotech names during extended trading.</p>
<div class="lb-trans"><p>美國週三的盤後交易中，多個小型和微型生物科技公司出現了一波上漲，既有催化劑驅動的波動，也有情緒驅動的反彈。雖然一些公司因即將到來的臨牀里程碑或最近的數據發佈而上漲，但其他公司儘管沒有新的公司動態，仍然上漲，反映出在延長交易期間對高波動性生物科技公司的重新關注。</p>
</div><p><em>Below are the notable after-hours gainers:</em></p>
<div class="lb-trans"><p><em>以下是顯著的盤後漲幅股：</em></p>
</div><p><strong>Agape ATP Corp. (ATPC) — Up 29.41% After Hours</strong></p>
<div class="lb-trans"><p><strong>Agape ATP Corp. (ATPC) — 盤後上漲 29.41%</strong></p>
</div><p>After hours: $0.088 (+29.41%)</p>
<div class="lb-trans"><p>盤後交易：$0.088 (+29.41%)</p>
</div><p>Close: $0.0680 (-94.83%)</p>
<div class="lb-trans"><p>收盤：$0.0680 (-94.83%)</p>
</div><p>Agape ATP surged in after-hours trading despite no company-specific news on Wednesday. The move appears to be part of a broader risk-on reaction in micro-cap names following the Fed's rate cut, which improved sentiment across speculative segments of the market.</p>
<div class="lb-trans"><p>儘管週三沒有公司特定的新聞，Agape ATP 在盤後交易中大幅上漲。這一走勢似乎是美聯儲降息後微型股的廣泛風險偏好反應，改善了市場投機性板塊的情緒。</p>
</div><p><strong>Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Up 12.76% After Hours</strong></p>
<div class="lb-trans"><p><strong>Corbus Pharmaceuticals Holdings, Inc. (CRBP) — 盤後上漲 12.76%</strong></p>
</div><p>After hours: $11.57 (+12.76%)</p>
<div class="lb-trans"><p>盤後交易：$11.57 (+12.76%)</p>
</div><p>Close: $10.26 (+1.58%)</p>
<div class="lb-trans"><p>收盤：$10.26 (+1.58%)</p>
</div><p>Corbus gained momentum ahead of a key clinical update. The company announced plans to release results from its Phase 1a SAD/MAD study of CRB-913 before the market opens on Thursday, December 11, 2025, followed by an 8:00 a.m. ET conference call. Anticipation around the data likely contributed to the strong after-hours move.</p>
<div class="lb-trans"><p>Corbus 在關鍵臨牀更新前獲得了動力。該公司宣佈計劃在 2025 年 12 月 11 日市場開盤前發佈 CRB-913 的 1a 期 SAD/MAD 研究結果，並將在東部時間上午 8:00 召開電話會議。對數據的期待可能促成了強勁的盤後走勢。</p>
</div><p><strong>Anebulo Pharmaceuticals, Inc. (ANEB) — Up 8.37% After Hours</strong></p>
<div class="lb-trans"><p><strong>Anebulo Pharmaceuticals, Inc. (ANEB) — 盤後上漲 8.37%</strong></p>
</div><p>After hours: $2.33 (+8.37%)</p>
<div class="lb-trans"><p>盤後交易：$2.33 (+8.37%)</p>
</div><p>Close: $2.15 (-6.52%)</p>
<div class="lb-trans"><p>收盤：$2.15 (-6.52%)</p>
</div><p>Anebulo rebounded sharply after hours despite no news on Wednesday. The gain aligns with the broader uptick in small-cap biotech sentiment following the Fed's rate decision.</p>
<div class="lb-trans"><p>儘管週三沒有新聞，Anebulo 在盤後交易中大幅反彈。這一漲幅與美聯儲利率決定後小型生物科技情緒的整體上升相一致。</p>
</div><p><strong>Cue Biopharma, Inc. (CUE) — Up 13.12% After Hours</strong></p>
<div class="lb-trans"><p><strong>Cue Biopharma, Inc. (CUE) — 盤後上漲 13.12%</strong></p>
</div><p>After hours: $0.54 (+13.12%)</p>
<div class="lb-trans"><p>盤後交易：$0.54 (+13.12%)</p>
</div><p>Close: $0.4773 (-3.50%)</p>
<div class="lb-trans"><p>收盤：$0.4773 (-3.50%)</p>
</div><p>Cue Biopharma posted a double-digit after-hours jump with no new corporate developments. The move appears to be macro-driven as investors rotated back into beaten-down biotech names.</p>
<div class="lb-trans"><p>Cue Biopharma 在沒有新的公司動態的情況下，盤後交易中出現了兩位數的跳漲。這一走勢似乎是宏觀驅動的，因為投資者重新回流到被打壓的生物科技股。</p>
</div><p><strong>Curis, Inc. (CRIS) — Up 7.68% After Hours</strong></p>
<div class="lb-trans"><p><strong>Curis, Inc. (CRIS) — 盤後上漲 7.68%</strong></p>
</div><p>After hours: $1.3999 (+7.68%)</p>
<div class="lb-trans"><p>盤後交易：$1.3999 (+7.68%)</p>
</div><p>Close: $1.30 (-2.26%)</p>
<div class="lb-trans"><p>收盤：$1.30 (-2.26%)</p>
</div><p>Curis traded higher after hours, extending momentum from its updated clinical data presented on December 9 at the 67th ASH Annual Meeting. The poster highlighted progress in the company's frontline AML triplet study (CA-4948-104), which continues to draw investor attention.</p>
<div class="lb-trans"><p>Curis 在盤後交易中上漲，延續了其在 12 月 9 日第 67 屆 ASH 年會上發佈的更新臨牀數據的勢頭。海報強調了該公司前線 AML 三聯療法研究（CA-4948-104）的進展，繼續吸引投資者關注。</p>
</div><p><strong>Skye Bioscience, Inc. (SKYE) — Up 7.02% After Hours</strong></p>
<div class="lb-trans"><p><strong>Skye Bioscience, Inc. (SKYE) — 盤後上漲 7.02%</strong></p>
</div><p>After hours: $1.22 (+7.02%)</p>
<div class="lb-trans"><p>盤後交易：$1.22 (+7.02%)</p>
</div><p>Close: $1.14 (-5.79%)</p>
<div class="lb-trans"><p>收盤：$1.14 (-5.79%)</p>
</div><p>Skye Bioscience saw a modest after-hours recovery despite no news on Wednesday, likely benefiting from the broader biotech lift tied to the Fed-driven market rally.</p>
<div class="lb-trans"><p>儘管週三沒有新聞，Skye Bioscience 在盤後交易中出現了適度的反彈，可能受益於與美聯儲驅動的市場反彈相關的生物科技整體上漲。</p>
</div><p><strong>Cerus Corporation (CERS) — Up 3.17% After Hours</strong></p>
<div class="lb-trans"><p><strong>Cerus Corporation (CERS) — 盤後上漲 3.17%</strong></p>
</div><p>After hours: $1.95 (+3.17%)</p>
<div class="lb-trans"><p>盤後交易：$1.95 (+3.17%)</p>
</div><p>Close: $1.89 (+1.61%)</p>
<div class="lb-trans"><p>收盤：$1.89 (+1.61%)</p>
</div><p>Cerus continued its upward trend after announcing a group purchasing agreement with Blood Centers of America (BCA). The deal covers the company's full INTERCEPT product line and aims to expand access to pathogen-reduction technologies across BCA's nationwide network.</p>
<div class="lb-trans"><p>Cerus 在宣佈與美國血液中心（BCA）達成團體採購協議後，繼續其上升趨勢。該協議涵蓋了公司的全系列 INTERCEPT 產品，旨在擴大 BCA 全國網絡中病原體去除技術的可及性。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需評論和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

盤後上漲股：生物科技股因數據預期和動量買盤而攀升